STOCK TITAN

Paragon 28 To Report Fourth Quarter and Full Year 2022 Financial Results on March 2, 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

Paragon 28, Inc. (NYSE: FNA), a leader in the foot and ankle orthopedic market, will release its financial results for Q4 and FY 2022 after market close on March 2, 2023. A conference call will follow at 4:30 p.m. ET, available for investors by dialing (844-200-6205) domestically and (929-526-1599) internationally, with conference ID 798665. The call will also be accessible via webcast on the company's investor website. Established in Englewood, Colo., Paragon 28 focuses on innovative orthopedic solutions aimed at improving patient outcomes in foot and ankle conditions.

Positive
  • None.
Negative
  • None.

ENGLEWOOD, Colo.--(BUSINESS WIRE)-- Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the fourth quarter and full year 2022 after market close on Thursday, March 2, 2023. The company’s management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by dialing (844-200-6205) for domestic callers or (929-526-1599) for international callers, using conference ID: 798665. Live audio of the webcast will be available on the “Investors” section of the company’s website at: ir.paragon28.com. The webcast will be archived and available for replay for at least 90 days after the event.

About Paragon 28, Inc.

Based in Englewood, Colo., Paragon 28, is a leading medical device company exclusively focused on the foot and ankle orthopedic market and is dedicated to improving patient lives. From the onset, Paragon 28® has provided innovative orthopedic solutions, procedural approaches and instrumentation that cover a wide range of foot and ankle ailments including fracture fixation, forefoot, ankle, progressive collapsing foot deformity (PCFD) or flatfoot, charcot foot and orthobiologics. The company designs products with both the patient and surgeon in mind, with the goal of improving outcomes, reducing ailment recurrence and complication rates, and making the procedures simpler, consistent, and reproducible.

Investor Contact:

Matthew Brinckman

Senior Vice President, Strategy and Investor Relations

Phone: (741) 336-0435

mbrinckman@paragon28.com

Source: Paragon 28, Inc.

FAQ

When will Paragon 28 report its Q4 2022 financial results?

Paragon 28 will report its Q4 2022 financial results after market close on March 2, 2023.

What time is the Paragon 28 conference call scheduled?

The conference call for Paragon 28 is scheduled for 4:30 p.m. ET on March 2, 2023.

How can I listen to Paragon 28's conference call?

Investors can listen to the conference call by dialing (844-200-6205) for domestic calls or (929-526-1599) for international calls, using conference ID 798665.

Where can I find the webcast for Paragon 28's conference call?

The webcast for the conference call will be available on the 'Investors' section of Paragon 28's website.

Paragon 28, Inc.

NYSE:FNA

FNA Rankings

FNA Latest News

FNA Stock Data

507.10M
83.54M
40.68%
60%
8.17%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
ENGLEWOOD